Skip to main content

Advertisement

SpringerLink
Log in

Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

The CD40 receptor is a member of the tumour necrosis factor receptor family and is widely expressed on various cell types. The antitumour activity of CD40 agonist antibody has been observed in B-cell-derived malignancies, but its activity on ovarian cancer remains unclear. However, in this paper, we first confirmed that the anti-CD40 agonist antibody could inhibit the growth of ovarian cancer cells and induce apoptosis. This study investigated the expression of CD40 by ovarian carcinoma tissues and cell lines, at the same time, we evaluated the effect of a recombinant soluble human CD40L (rshCD40L) and an anti-CD40 agonist antibody on cell growth and apoptosis. Flow cytometry and immunohistochemistry assay demonstrated that CD40 was expressed on ovarian carcinoma cell lines and primary ovarian carcinoma cells derived from ascites, as well as on ovarian carcinoma tissues. The growth inhibition of rshCD40L and the anti-CD40 agonist antibody on ovarian carcinoma cells was examined by MTT assay, and the proportion of apoptotic tumour cells was analysed by flow cytometry and Hoechst staining. Our study showed that CD40 was expressed on all ovarian carcinoma cell lines and was examined in 86.2% (162/188) of ovarian cancer tissue samples, but not in normal ovarian tissues (n = 20). Treatment with rshCD40L or anti-CD40 agonist antibody significantly inhibited ovarian carcinoma cell growth and induced apoptosis. Theses results suggest that CD40 is expressed on ovarian carcinoma cells, moreover, that rshCD40L and anti-CD40 agonist antibody have therapeutic potential to inhibit human ovarian cancer growth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK (2009) Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 15(8):2695–2702. doi:1078-0432.CCR-08-2966

    Article  PubMed  Google Scholar 

  2. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ (2009) Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48–52. doi:S0090-8258(09)00139-5

    Article  PubMed  Google Scholar 

  3. Gerestein CG, Eijkemans MJ, de Jong D, van der Burg ME, Dykgraaf RH, Kooi GS, Baalbergen A, Burger CW, Ansink AC (2009) The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG 116(3):372–380. doi:10.1111/j.1471-0528.2008.02033.x

    Article  PubMed  CAS  Google Scholar 

  4. Chiodoni C, Iezzi M, Guiducci C, Sangaletti S, Alessandrini I, Ratti C, Tiboni F, Musiani P, Granger DN, Colombo MP (2006) Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 203(11):2441–2450. doi:jem.20060844

    Article  PubMed  CAS  Google Scholar 

  5. Maisch T, Kropff B, Sinzger C, Mach M (2002) Upregulation of CD40 expression on endothelial cells infected with human cytomegalovirus. J Virol 76(24):12803–12812

    Article  PubMed  CAS  Google Scholar 

  6. Castigli E, Wilson SA, Elkhal A, Ozcan E, Garibyan L, Geha RS (2007) Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation. J Allergy Clin Immunol 120(4):885–891. doi:10.1016/j.jaci.2007.06.012

    Article  PubMed  CAS  Google Scholar 

  7. Luczynski W, Kowalczuk O, Ilendo E, Stasiak-Barmuta A, Krawczuk-Rybak M (2007) Upregulation of antigen-processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation. Ann Hematol 86(5):339–345. doi:10.1007/s00277-007-0256-z

    Article  PubMed  CAS  Google Scholar 

  8. Vanden Bush TJ, Bishop GA (2008) TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur J Immunol 38(2):400–409. doi:10.1002/eji.200737602

    Article  Google Scholar 

  9. Burysek L, Syrovets T, Simmet T (2002) The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. J Biol Chem 277(36):33509–33517. doi:10.1074/jbc.M201941200

    Article  PubMed  CAS  Google Scholar 

  10. Lefrancois L, Altman JD, Williams K, Olson S (2000) Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells. J Immunol 164(2):725–732. doi:ji_v164n2p725

    PubMed  CAS  Google Scholar 

  11. Villarroel Dorrego M, Speight PM, Barrett AW (2007) CD40 in human oral epithelia. Oral Oncol 43(7):626–633. doi:S1368-8375(06)00317-4

    Article  PubMed  Google Scholar 

  12. Lee JK, Seki N, Sayers TJ, Subleski J, Gruys EM, Murphy WJ, Wiltrout RH (2005) Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L. Cell Immunol 235(2):145–152. doi:10.1016/j.cellimm.2005.08.029

    Article  PubMed  CAS  Google Scholar 

  13. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY (2008) Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol 30(4):295–299

    PubMed  CAS  Google Scholar 

  14. Jang TJ (2002) Expression of CD40 and Fas ligand in Bowen’s disease, squamous cell carcinoma and basal cell carcinoma. Yonsei Med J 43(3):304–308

    PubMed  CAS  Google Scholar 

  15. Wu JQ, Zhao WH, Yin KS, Cheng YL (2007) Adeno-associated virus-mediated CD40 ligand transfer into human lung cancer cells. Zhonghua Zhong Liu Za Zhi 29(4):253–257

    PubMed  CAS  Google Scholar 

  16. Zhou Z, Shi Q, Wang J, Pan J, Zhang X (2000) Anti-CD40 McAb induces CD40+ malignant B cell proliferation arrest and apoptosis. Zhonghua Xue Ye Xue Za Zhi 21(5):237–239. doi:10.1016/j.oraloncology.2006.12.008

  17. Dzojic H, Loskog A, Totterman TH, Essand M (2006) Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 66(8):831–838. doi:10.1002/pros.20344

    Article  PubMed  CAS  Google Scholar 

  18. Villarroel Dorrego M, Whawell SA, Speight PM, Barrett AW (2006) Transfection of CD40 in a human oral squamous cell carcinoma keratinocyte line upregulates immune potency and costimulatory molecules. Br J Dermatol 154(2):231–238. doi:10.1111/j.1365-2133.2005.07006.x

    Article  PubMed  CAS  Google Scholar 

  19. Mayr C, Kofler DM, Buning H, Bund D, Hallek M, Wendtner CM (2005) Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood 106(9):3223–3226

    Article  PubMed  CAS  Google Scholar 

  20. Morel Y, Truneh A, Sweet RW, Olive D, Costello RT (2001) The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J Immunol 167(5):2479–2486

    PubMed  CAS  Google Scholar 

  21. von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T, Korsgren O, Totterman TH (2008) Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 31(4):377–384. doi:10.1097/CJI.0b013e31816a812d

    Article  Google Scholar 

  22. Zhou H, Xi H, Ma QR, Chen C, Zhang F, Zhang XG, Gu ZJ (2007) Therapeutic effect of agonistic CD40 monoclonal antibody combined with CTL on hu-SCID mouse B lymphoma model. Zhonghua Zhong Liu Za Zhi 29(3):181–185

    PubMed  CAS  Google Scholar 

  23. Wu Y, Wang L, He X, Xu H, Zhou L, Zhao F, Zhang Y (2008) Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo. Cell Immunol 253(1–2):102–109. doi:S0008-8749(08)00103-2

    Article  PubMed  CAS  Google Scholar 

  24. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229:152–172

    Article  PubMed  CAS  Google Scholar 

  25. Li R, Chen WC, Pang XQ, Zhang XG (2009) Expression of CD40 in human gastric cancer tissue and its prognostic correlation. Zhonghua Yi Xue Za Zhi 89(30):2124–2128

    PubMed  CAS  Google Scholar 

  26. Bereznaya NM, Chekhun VF (2007) Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. Exp Oncol 29(1):2–12

    PubMed  CAS  Google Scholar 

  27. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM Jr (1999) Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res 5(8):2261–2270

    PubMed  CAS  Google Scholar 

  28. Melichar B, Patenia R, Gallardo S, Melicharova K, Hu W, Freedman RS (2007) Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecol Oncol 104(3):707–713. doi:10.1016/j.ygyno.2006.10.056

    Article  PubMed  CAS  Google Scholar 

  29. Hollmann A, Aloyz R, Baker K, Dirnhofer S, Owens T, Sladek R, Tzankov A (2010) Vav-1 expression correlates with NFkappaB activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines. Hematol Oncol 28(3):142–150. doi:10.1002/hon.935

    PubMed  CAS  Google Scholar 

  30. Fotin-Mleczek M, Henkler F, Hausser A, Glauner H, Samel D, Graness A, Scheurich P, Mauri D, Wajant H (2004) Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation. J Biol Chem 279(1):677–685. doi:10.1074/jbc.M310969200

    Article  PubMed  CAS  Google Scholar 

  31. Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ (2007) TRAF proteins in CD40 signaling. Adv Exp Med Biol 597:131–151. doi:10.1007/978-0-387-70630-6_11

    Article  PubMed  Google Scholar 

  32. Jiang E, He X, Chen X, Sun G, Wu H, Wei Y, Zhao X (2008) Expression of CD40 in ovarian cancer and adenovirus-mediated CD40 ligand therapy on ovarian cancer in vitro. Tumori 94(3):356–361

    PubMed  Google Scholar 

  33. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS (2005) Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 65(18):8331–8338. doi:10.1158/0008-5472.CAN-05-0095

    Article  PubMed  CAS  Google Scholar 

  34. Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, Oflazoglu E, Grewal IS (2006) Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 148(8):1116–1123

    Article  PubMed  CAS  Google Scholar 

  35. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC (2004) Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 64(8):2846–2852

    Article  PubMed  CAS  Google Scholar 

  36. Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N (2010) A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 95(5):845–848. doi:10.3324/haematol.2009.008003

    Article  PubMed  CAS  Google Scholar 

  37. Ronald PG, Timothy P, Susan HC et al. (2011) The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother. doi:10.1007/s00262-011-1014-6

  38. Tutt AL, O’Brien L, Hussain A, Crowther GR, French RR, Glennie MJ (2002) T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 168(6):2720–2728

    PubMed  CAS  Google Scholar 

  39. Davis ID, Chen Q, Morris L et al (2006) Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother 29:499–511

    Article  PubMed  Google Scholar 

  40. French RR, Chan HT, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T cell response that eradicates lymphoma and bypasses T cell help. Nat Med 5:548–553

    Article  PubMed  CAS  Google Scholar 

  41. Mackey MF, Gunn JR, Ting PP et al (1997) Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res 57:2569–2574

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Keyuan Road 4, Chengdu, 610041, Sichuan, China

    Yan Zhou, Jing He, Lan-tu Gou, Bo Mu, Wei-chan Liao, Cong Ma, Ping Tang, Shi-jie Zhou, Yong-jun Zhou & Jin-liang Yang

Authors
  1. Yan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lan-tu Gou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bo Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei-chan Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cong Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ping Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shi-jie Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yong-jun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jin-liang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin-liang Yang.

Additional information

Yan Zhou and Jing He contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, Y., He, J., Gou, Lt. et al. Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells. Cancer Immunol Immunother 61, 1735–1743 (2012). https://doi.org/10.1007/s00262-011-1194-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-011-1194-0

Keywords

Search

Navigation